Navigation Links
MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
Date:1/26/2009

rally inhaled acute migraine medication in development which has a multi-targeted mechanism of action, utilizes the company's proprietary TEMPO(R) inhaler and is designed to optimize the key characteristics of dihydroergotamine, an active ingredient which has been used to effectively and safely treat migraines for over 60 years. MAP0004 has the potential to provide a faster onset of action than currently available migraine treatments, with sustained pain relief and pain freedom, in an easy-to-use, non-invasive, at-home therapy. In a Phase 2 clinical trial, patients reported pain relief in as fast as 10 minutes, with sustained relief to 24 and 48 hours. The safety data generated to date have shown MAP0004 to be well tolerated with no significant adverse events reported.

Migraine is a common, debilitating neurological disease affecting approximately 30 million people in the United States, according to the National Headache Foundation (NHF). Common symptoms include recurrent attacks of headaches, nausea, vomiting and sensitivity to light and sound. According to the NHF, most migraines last between four and 24 hours, but some last as long as three days. On average, migraine sufferers experience 1.5 migraine attacks monthly, although 25 percent of them experience one or more attacks weekly, according to published studies.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical trials. Unit Dose Budesonide is being developed for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technolo
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Axikin Pharmaceuticals Spins out of Actimis
2. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
3. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
4. Cumberland Pharmaceuticals Appoints Lee Product Director
5. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
6. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
7. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
8. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
9. Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
10. MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
11. Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... 03, 2015 , ... Nine field days to promote practices that improve soil ... Soil Health Partnership , the field days will demonstrate how changing certain practices, ... productivity and income. , Brent Bible has practiced no-till farming and planted cover crops ...
(Date:8/3/2015)...   Intrexon Corporation (NYSE: XON ) ... quarter 2015 financial results after the market closes on ... host a conference call at 5:30 PM ET to ... The conference call may be accessed by ... to join the "Intrexon Corporation Call."  Participants may also ...
(Date:8/3/2015)... WA (PRWEB) , ... August 03, 2015 , ... ... and TLD5000 diaphragm vacuum pumps to its comprehensive line of analytical laboratory equipment. ... steel valves, these versatile pumps provide a chemically resistant and maintenance-free solution for ...
(Date:7/31/2015)... July 31, 2015 China Cord Blood Corporation ... leading provider of cord blood collection, laboratory ... services, today announced that the Company has filed its ... and Exchange Commission. The filed Form 20-F includes audited ... 2015. The Form 20-F can be accessed by visiting ...
Breaking Biology Technology:Soil Health Field Days Kick Off Throughout Midwest 2Soil Health Field Days Kick Off Throughout Midwest 3Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2Sterlitech Launches New Line of Vacuum Pumps 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2
... 1 Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ... Bisaro, Watson,s president and chief,executive officer, will provide ... the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and,Medical ... 1:40 p.m. Eastern,Standard Time., This presentation will ...
... Bulletin Board: CARN) today announced the,settlement of a lawsuit ... the settlement was not disclosed. Carrington maintains its,position and ... eager to focus our full attention to analyzing our ... and needed to resolve,some outstanding issues that occupied our ...
... 1 Edwards Lifesciences,Corporation (NYSE: EW ), ... advanced cardiovascular disease, is scheduled to participate in ... at the Grand Hyatt Hotel in New York ... Edwards Lifesciences, corporate vice president, chief,financial officer & ...
Cached Biology Technology:Carrington Settles Lawsuit, Sets Sights On Future 2Carrington Settles Lawsuit, Sets Sights On Future 3Edwards Lifesciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
(Date:7/2/2015)... , June 25, 2015 ... addition of the "Next Generation Biometrics Market by ... 2020" report to their offering. The ... Billion by 2020, at a CAGR of 17.9% between ... the leading application for the market. Safran SA ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... his Mongol hordes had an impact on the global carbon ... Black Death, on the other hand, came and went too ... the global carbon budget. Dwarfing both of these events, however, ... centuries has released vast amounts of carbon dioxide into the ...
... about Terminator. Instead, watch a tadpole turn into a frog. ... what University of Vermont roboticist Josh Bongard has discovered, as ... Proceedings of the National Academy of Sciences . ... robots that, like tadpoles becoming frogs, change their body forms ...
... with National Institute of Standards and Technology (NIST) scientists at ... for the first time that mercury cycling in the flora ... amount of ice cover present. Their study* is the latest ... (STAMP), a multiyear joint effort of NIST, the U.S. Fish ...
Cached Biology News:War, plague no match for deforestation in driving CO2 buildup 2For robust robots, let them be babies first 2For robust robots, let them be babies first 3For robust robots, let them be babies first 4Eggs show arctic mercury cycling may be linked to ice cover 2
Rabbit polyclonal to ATF4 (phospho S245) ( Abpromise for all tested applications). Antigen: Synthetic phosphopeptide derived from human ATF4 around the phosphorylation site of Serine 245. En...
Evolutionarily conserved signaling intermediate in Toll pathway...
Amino-acids and Derivatives Rabbit Anti-conjugated L-isoleucine Polyclonal Antibody...
Phosphatidylinositol transfer protein beta isoform (PtdIns transfer protein beta) (PtdInsTP) (PI-TP-beta). [Source:Uniprot/SWISSPROT;Acc:P48739] Antigen: Recombinant Protein Epitope Signature Tag...
Biology Products: